Premium
Towards HBV curative therapies
Author(s) -
Schinazi Raymond F.,
Ehteshami Maryam,
Bassit Leda,
Asselah Tarik
Publication year - 2018
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13656
Subject(s) - hepatitis b virus , medicine , hepatocellular carcinoma , crispr , effector , hepatitis b , therapeutic modalities , discontinuation , virology , immunology , intensive care medicine , virus , biology , cancer research , biochemistry , gene
Tremendous progress has been made over the last 2 decades to discover and develop approaches to control hepatitis B virus ( HBV ) infections and to prevent the development of hepatocellular carcinoma using various interferons and small molecules as antiviral agents. However, none of these agents have significant impact on eliminating HBV from infected cells. Currently the emphasis is on silencing or eliminating ccc DNA , which could lead to a cure for HBV . Various approaches are being developed including the development of capsid effectors, CRISPR /Cas9, TALENS , si RNA , entry and secretion inhibitors, as well as immunological approaches. It is very likely that a combination of these modalities will need to be employed to successfully eliminate HBV or prevent virus rebound on discontinuation of therapy. In the next 5 years clinical data will emerge which will provide insight on the safety and feasibility of these approaches and if they can be applied to eradicate HBV infections globally. In this review, we summarize current treatments and we highlight and examine recent therapeutic strategies that are currently being evaluated at the preclinical and clinical stage.